Highlights from the 74th Congress of the European Atherosclerosis Society.
Rabasseda
Xavier
X
Medical Information Department, Prous Science. xrabasseda@prous.com
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy; D002784:Cholesterol / Q000378:metabolism; D002995:Clofibric Acid / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000628:therapy; D047492:Peroxisome Proliferator-Activated Receptors / Q000627:therapeutic use
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D047492:Peroxisome Proliferator-Activated Receptors; D002995:Clofibric Acid; D002784:Cholesterol